Drug · DIN 02430355
ELOCTATE
KIT CONTAINING: A) SINGLE-USE VIAL (POWDER) AND B) DILUENT (PREFILLED SYRINGE)
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 13, 2022; first marketed January 15, 2016.
- Drug Identification Number (DIN)
- 02430355
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Powder For Solution; Kit
- Route
- Intravenous
- Therapeutic class (ATC)
- Coagulation factor viii B02BD02
- Class
- Human
- Record last updated
- September 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN | 3000 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 17, 2017: NOC 19312New Drug Submission (NDS) · Merger - buyout
- August 22, 2014: NOC 15991New Drug Submission (NDS)
Other DINs named ELOCTATE
- DIN 02430290 · Marketed
- DIN 02430304 · Marketed
- DIN 02430312 · Marketed
- DIN 02430320 · Marketed
- DIN 02430339 · Marketed
- DIN 02430347 · Marketed